The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Efficacy and Safety of ABT‐494, a Selective JAK‐1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Open accessAbstract
Objective: To evaluate the efficacy and safety of ABT‐494, a selective JAK‐1 inhibitor, in patients with moderate‐to‐severe rheumatoid arthritis (RA) and an inadequate response to methotrexate (MTX). Methods: Three hundred RA patients receiving stable doses of MTX were randomly assigned equally to receive immediate‐release ABT‐494 at 3, 6, 12, or 18 mg twice daily, 24 mg once daily, or placebo for 12 weeks. The primary efficacy end point was the proportion of patients meeting the American College of Rheumatology 20% improvement criteria (achieving an ACR20 response) at week 12, as determined using the last observation carried forward method. Results: At week 12, the proportion of ACR20 responses was higher with ABT‐494 (62%, 68%, 80%, 64%, and 76% for the 3, 6, 12, 18, and 24 mg doses, respectively) than with placebo (46%) (using nonresponder imputation) (P < 0.05 for the 6, 12, and 24 mg doses). There was a significant dose‐response relationship among all ABT‐494 doses (P < 0.001). The proportions of patients achieving ACR50 and ACR70 responses were significantly higher for all ABT‐494 doses (except the 12 mg dose for the ACR70 response) than for placebo, as were changes in the Disease Activity Score in 28 joints using the C‐reactive protein level (DAS28‐CRP). Rapid improvement was demonstrated by significant differences in ACR20 response rates and changes in the DAS28‐CRP for all doses compared with placebo at week 2 (the first postbaseline visit). The incidence of adverse events was similar across groups; most were mild, and infections were the most frequent. One serious infection (community‐acquired pneumonia) occurred with ABT‐494 at 12 mg. There were dose‐dependent increases in high‐density lipoprotein (HDL) and low‐density lipoprotein (LDL) cholesterol, but the LDL cholesterol:HDL cholesterol ratios were unchanged through week 12. Mean hemoglobin levels remained stable at lower doses, but decreases were observed at higher doses. Conclusion: This study evaluated a broad range of doses of ABT‐494 in RA patients with an inadequate response to MTX. ABT‐494 demonstrated efficacy, with a safety and tolerability profile similar to that of other JAK inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Pathogenesis of Rheumatoid Arthritis
McInnes, I. B., & Schett, G. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1004965 · Cited by 5,514
Isaacs, J. D., Harari, O., Kobold, U., Lee, J. S., & Bernasconi, C. (2013) · Arthritis Research & Therapy · doi:10.1186/ar4397 · Cited by 105
Cited by
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Schwartz, D. M., Kanno, Y., Villarino, A., Ward, M., Gadina, M., & O'Shea, J. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.201 · Cited by 1,266
Banerjee, S., Biehl, A., Gadina, M., Hasni, S., & Schwartz, D. M. (2017) · Drugs · doi:10.1007/s40265-017-0701-9 · Cited by 1,206
The role of JAK/STAT signaling pathway and its inhibitors in diseases.
Xin, P., Xu, X., Deng, C., Liu, S., Wang, Y., Zhou, X., Ma, H., Wei, D., & Sun, S. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106210 · Cited by 1,010
Interleukin-6: designing specific therapeutics for a complex cytokine
Garbers, C., Heink, S., Korn, T., & Rose-John, S. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.45 · Cited by 643
Banerjee, S., Biehl, A., Gadina, M., Hasni, S., & Schwartz, D. M. (2017) · Drugs · doi:10.1007/s40265-017-0736-y · Cited by 590
The emerging safety profile of JAK inhibitors in rheumatic disease
Winthrop, K. L. (2017) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2017.23 · Cited by 590
Fleischmann, R., Pangan, A. L., Song, I., Mysler, E., Bessette, L., Peterfy, C., Durez, P., Ostor, A. J., Li, Y., Zhou, Y., et al. (2019) · Arthritis & Rheumatology · doi:10.1002/art.41032 · Cited by 444
Self-citationGenovese, M. C., Fleischmann, R., Combe, B., Hall, S., Rubbert-Roth, A., Zhang, Y., Zhou, Y., Mohamed, M.-E. F., Meerwein, S., & Pangan, A. L. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31116-4 · Cited by 422
Self-citationDougados, M., van der Heijde, D., Chen, Y.-C., Greenwald, M., Drescher, E., Liu, J., Beattie, S., Witt, S., de la Torre, I., Gaich, C., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210094 · Cited by 404
Erratum: JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Schwartz, D. M., Kanno, Y., Villarino, A., Ward, M., Gadina, M., & O'Shea, J. J. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.267 · Cited by 394
In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)
Parmentier, J. M., Voss, J., Graff, C., Schwartz, A., Argiriadi, M., Friedman, M., Camp, H. S., Padley, R. J., George, J. S., Hyland, D., et al. (2018) · BMC Rheumatology · doi:10.1186/s41927-018-0031-x · Cited by 390
Self-citationBurmester, G. R., Kremer, J. M., Van den Bosch, F., Kivitz, A., Bessette, L., Li, Y., Zhou, Y., Othman, A. A., Pangan, A. L., & Camp, H. S. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31115-2 · Cited by 373
Self-citationvan der Heijde, D., Song, I.-H., Pangan, A. L., Deodhar, A., van den Bosch, F., Maksymowych, W. P., Kim, T.-H., Kishimoto, M., Everding, A., Sui, Y., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32534-6 · Cited by 357
Self-citationOlivera, P. A., Lasa, J. S., Bonovas, S., Danese, S., & Peyrin-Biroulet, L. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.001 · Cited by 330
Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn’s Disease
Sandborn, W. J., Feagan, B. G., Loftus, E. V., Peyrin-Biroulet, L., Van Assche, G., D’Haens, G., Schreiber, S., Colombel, J.-F., Lewis, J. D., Ghosh, S., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.047 · Cited by 322
“In 2 dose-ranging studies of patients with RA, upadacitinib 6 and 12 mg twice daily appeared to maximize efficacy.(23,24) In contrast, in CELEST, the 24-mg twice daily induction dose was generally more effective, particularly for the endoscopic endpoints, hsCRP, and quality of life measures in patients with moderately…”
BackgroundSelf-citationCurrent and future status of JAK inhibitors
McLornan, D. P., Pope, J. E., Gotlib, J., & Harrison, C. N. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00438-4 · Cited by 305
JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis
Fragoulis, G. E., McInnes, I. B., & Siebert, S. (2019) · Rheumatology · doi:10.1093/rheumatology/key276 · Cited by 296
Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis
Sandborn, W. J., Ghosh, S., Panes, J., Schreiber, S., D’Haens, G., Tanida, S., Siffledeen, J., Enejosa, J., Zhou, W., Othman, A. A., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.02.030 · Cited by 289
Self-citationBechman, K., Subesinghe, S., Norton, S., Atzeni, F., Galli, M., Cope, A. P., Winthrop, K. L., & Galloway, J. B. (2019) · Rheumatology · doi:10.1093/rheumatology/kez087 · Cited by 287
Clinical significance of Janus Kinase inhibitor selectivity
Choy, E. H. (2019) · Rheumatology · doi:10.1093/rheumatology/key339 · Cited by 285
McInnes, I. B., Byers, N. L., Higgs, R. E., Lee, J., Macias, W. L., Na, S., Ortmann, R. A., Rocha, G., Rooney, T. P., Wehrman, T., et al. (2019) · Arthritis Research & Therapy · doi:10.1186/s13075-019-1964-1 · Cited by 281
Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases
Virtanen, A. T., Haikarainen, T., Raivola, J., & Silvennoinen, O. (2019) · BioDrugs · doi:10.1007/s40259-019-00333-w · Cited by 281
Interleukin-6: obstacles to targeting a complex cytokine in critical illness
McElvaney, O. J., Curley, G. F., Rose-John, S., & McElvaney, N. G. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00103-x · Cited by 278
JAK inhibitors for the treatment of autoimmune and inflammatory diseases
Jamilloux, Y., El Jammal, T., Vuitton, L., Gerfaud-Valentin, M., Kerever, S., & Sève, P. (2019) · Autoimmunity Reviews · doi:10.1016/j.autrev.2019.102390 · Cited by 264
Klünder, B., Mohamed, M.-E. F., & Othman, A. A. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0605-6 · Cited by 83
Self-citation
Metadata
- Authors
- Genovese, M. C., Smolen, J. S., Weinblatt, M. E., Burmester, G. R., Meerwein, S., Camp, H. S., Wang, L., Othman, A. A., Khan, N., Pangan, A. L., & Jungerwirth, S.
- Venue
- Arthritis & Rheumatology
- Publisher
- Wiley
- Published
- 2016-11-28
- Volume
- 68
- Issue
- 12
- Pages
- 2857-2866
- ISSN
- 2326-5191 (ISSN-L)
- 2326-5205
- OpenAlex
- W2559743688
- Cited by
- 200
- References
- 2
- FWCI
- 25.58
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.